Deksloksiglumid

Deksloksiglumid
(IUPAC) ime
	(4R)-4-[(3,4-dichlorobenzoyl)amino]-5-(3-methoxypropylpentylamino)-5-oxopentanoic acid
Klinički podaci
Identifikatori
CAS broj	119817-90-2
ATC kod	nije dodeljen
PubChem	65937
Hemijski podaci
Formula	C21H30Cl2N2O5
Mol. masa	461.379 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1 ; Key: QNQZBKQEIFTHFZ-GOSISDBHSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Deksloksiglumid je lek koji deluje kao holecistokininski antagonist, koji je selektivan za CCK_A tip receptora. On inhibira gastrointestinalnu motilnost i redukuje želudačnu sekreciju. Mada stariji selektivni CCK_A antagonisti poput lorglumida i devazepida nisu dospeli do kliničkih upotrebe, deksloksiglumid se istražuje kao potencijalni lek za niz gastrointestinalnih problema, među kojima je upalna bolest creva,^[3] dispepsija,^[4] konstipacija^[5] i pankreatitis.^[6]^[7]

Literatura[uredi - уреди | uredi izvor]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
↑ Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, Thomforde G, Urrutia R, Zinsmeister AR. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. American Journal of Gastroenterology. 2005 Mar;100(3):652-63. PMID 15743365
↑ Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterology and Motility. 2005 Oct;17(5):643-53. PMID 16185302
↑ Roberts DJ, Banh HL, Hall RI. Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients. Current Opinion in Critical Care. 2006 Aug;12(4):295-302. PMID 16810038
↑ Maselli MA, Mennuni L. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterologica e Dietologica. 2003 Sep;49(3):211-6. PMID 16484960
↑ Barrett TD, Yan W, Freedman JM, Lagaud GJ, Breitenbucher JG, Shankley NP. Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction. British Journal of Pharmacology. 2008 Apr;153(8):1650-8. PMID 18297100

Spoljašnje veze[uredi - уреди | uredi izvor]

	Portal Medicina
	Portal Hemija

Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.

[3] Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, Thomforde G, Urrutia R, Zinsmeister AR. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. American Journal of Gastroenterology. 2005 Mar;100(3):652-63. PMID 15743365

[4] Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterology and Motility. 2005 Oct;17(5):643-53. PMID 16185302

[5] Roberts DJ, Banh HL, Hall RI. Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients. Current Opinion in Critical Care. 2006 Aug;12(4):295-302. PMID 16810038

[6] Maselli MA, Mennuni L. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterologica e Dietologica. 2003 Sep;49(3):211-6. PMID 16484960

[7] Barrett TD, Yan W, Freedman JM, Lagaud GJ, Breitenbucher JG, Shankley NP. Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction. British Journal of Pharmacology. 2008 Apr;153(8):1650-8. PMID 18297100

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Deksloksiglumid

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Navigacijski meni

Lični/osobni alati

Imenski prostori

Varijante

Pregledi

Više

Traži-Тражи

Orijentacija-Оријентација

interakcija - интеракција

Ispis/izvoz

Alatke-Алатке

Na drugim jezicima